Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Glucosamine research

This article was originally published in The Tan Sheet

Executive Summary

"Long-term treatment with glucosamine sulfate retarded the progression of knee osteoarthritis, possibly determining disease modification," according to study published in recent Archives of Internal Medicine. More than 200 patients with knee OA received either 1,500 mg glucosamine sulfate or placebo in randomized, double-blind trial conducted by Karel Pavelka, MD/PhD, Charles University, Prague, et al. After three years, glucosamine arm showed "no average change" in joint space narrowing, while placebo group experienced significantly greater narrowing of -.19 mm. Symptoms also improved as much as 20%-25% in glucosamine group, only "modestly" for control...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS094761

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel